Allergy Therapeutics (AGY) — Cash Flow-to-Debt Ratio
Allergy Therapeutics (AGY) has a Cash Flow-to-Debt Ratio of -0.22x as of June 2025, meaning its operating cash flow of GBX-21.09 Million could theoretically repay 0% of its total liabilities (GBX95.74 Million) in one year. See free cash flow generation of Allergy Therapeutics to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Allergy Therapeutics Cash Flow-to-Debt Ratio (2002–2025)
Historical debt coverage capacity for Allergy Therapeutics across 24 annual periods. Also explore AGY shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Allergy Therapeutics (2002–2025)
Year-by-year debt coverage analysis for Allergy Therapeutics. For market capitalisation and broader financial context, see AGY stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.30x | GBX-28.72 Million | GBX95.74 Million | ▲ +43.0% |
| 2024 | -0.53x | GBX-32.14 Million | GBX61.12 Million | ▼ -10.1% |
| 2023 | -0.48x | GBX-30.92 Million | GBX64.70 Million | ▼ -19.1% |
| 2022 | -0.40x | GBX-14.11 Million | GBX35.18 Million | ▼ -286.3% |
| 2021 | 0.22x | GBX8.52 Million | GBX39.55 Million | ▼ -25.6% |
| 2020 | 0.29x | GBX12.28 Million | GBX42.44 Million | ▲ +59.8% |
| 2019 | 0.18x | GBX5.60 Million | GBX30.94 Million | ▲ +233.2% |
| 2018 | -0.14x | GBX-3.80 Million | GBX27.98 Million | ▼ -2177.6% |
| 2017 | 0.01x | GBX178.00K | GBX27.22 Million | ▲ +101.5% |
| 2016 | -0.45x | GBX-11.84 Million | GBX26.36 Million | ▼ -333.5% |
| 2015 | 0.19x | GBX3.12 Million | GBX16.23 Million | ▲ +18.0% |
| 2014 | 0.16x | GBX2.17 Million | GBX13.32 Million | ▼ -4.1% |
| 2013 | 0.17x | GBX2.43 Million | GBX14.29 Million | ▼ -22.2% |
| 2012 | 0.22x | GBX2.88 Million | GBX13.16 Million | ▲ +407.5% |
| 2011 | -0.07x | GBX-2.03 Million | GBX28.48 Million | ▼ -205.5% |
| 2010 | 0.07x | GBX1.70 Million | GBX25.23 Million | ▲ +793.8% |
| 2009 | -0.01x | GBX-440.00K | GBX45.25 Million | ▲ +98.3% |
| 2008 | -0.56x | GBX-19.32 Million | GBX34.47 Million | ▲ +54.3% |
| 2007 | -1.23x | GBX-18.88 Million | GBX15.40 Million | ▲ +21.7% |
| 2006 | -1.56x | GBX-8.10 Million | GBX5.18 Million | ▼ -17953.9% |
| 2005 | -0.01x | GBX-57.00K | GBX6.58 Million | ▼ -101.9% |
| 2004 | 0.46x | GBX1.91 Million | GBX4.16 Million | ▲ +22.6% |
| 2003 | 0.37x | GBX2.10 Million | GBX5.60 Million | ▲ +362.1% |
| 2002 | -0.14x | GBX-2.01 Million | GBX14.07 Million | — |